Wilson Sonsini Goodrich & Rosati advised investor Novo Holdings on the transaction. Obsidian Therapeutics, Inc. (Obsidian), a clinical-stage biotechnology company, announced it closed an oversubscribed $160.5...
Obsidian’s $160.5 Million Series C Financing Round
Arcellx’s Expansion of Partnership with Kite
Wilson Sonsini Goodrich & Rosati is advising Arcellx on the transaction. Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD) announced that they have...
LENZ Therapeutics’ Merger with Graphite Bio
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
MapLight Therapeutics’ $225 Million Series C Funding Round
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction. MapLight Therapeutics announced a $225 million Series C financing co-led by Novo Holdings, 5AM Ventures, Cowen...
Avalyn Pharma’s $175 Million Series C Financing Round
Wilson Sonsini Goodrich & Rosati advised Novo Holdings A/S and Vida Ventures on the transaction. Avalyn Pharma Inc. announced the closing of an oversubscribed $175 million...
Forte Biosciences’ $25 Million Financing
Wilson Sonsini Goodrich & Rosati represented Forte Biosciences in the transaction. Forte Biosciences (NASDAQ: FBRX) announced key R&D updates for its product candidate FB-102 (a proprietary molecule...
Nexo Therapeutics’ $60 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised Versant Ventures and New Enterprise Associates on the deal. Nexo Therapeutics (Nexo) announced it has emerged from stealth with $60 million...
SpyGlass Pharma’s $90 Million Series C Financing
Wilson Sonsini Goodrich & Rosati represented SpyGlass in the transaction. SpyGlass Pharma announced the closing of $90 million in Series C financing. The financing, which was led...
Delve Bio’s $35 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised Delve Bio in the transaction. Delve Bio announced it has debuted with $35 million in Series A financing led by Perceptive...
LENZ Therapeutics’ $83.5 Million Series B Financing
Wilson Sonsini Goodrich & Rosati represented LENZ in the transaction. Biopharmaceutical company LENZ Therapeutics announced that it raised $83.5 million in an oversubscribed Series B financing....
Metagenomi’s $100 Million Series B Extension Financing
Wilson Sonsini Goodrich & Rosati advised Novo Holdings and Metagenomi on the deal. Fenwick represented Metagenomi. Gene editing company Metagenomi announced a $100 million Series B...
Arcellx’s $4 Billion Collaboration with Kite
Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction. Clinical-stage biotechnology company Arcellx and Gilead-owned biopharmaceutical company Kite announced a global strategic collaboration to develop...